Wisconsin Alumni Research Foundation

Technology

NEUTRALIZING VACCINES AGAINST HUMAN CORONAVIRUS

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocaps...
Learn More
Adel Talaat, Shaswath Chandrasekar | P210042US02

Technology

COVID-19 Vaccine

Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non­toxic tetanus toxin varia...
Learn More
Joseph Barbieri, Eric Johnson, Sabine Pellett, William Tepp, Amanda Przedpelski | P200268US03

Technology

RSV Virus-Like Particles And Methods Of Use Thereof

The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More
Elizabeth Wright, Larry Anderson, Binh Ha | P200021US02

Technology

Influenza Virus Replication For Vaccine Development

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More
Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping | P150360US02

Technology

Vaccines Comprising Mutant Attenuated Influenza Viruses

The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant ...
Learn More
Yoshihiro Kawaoka, Shinji Watanabe, Tokiko Watanabe | P100251US02

Technology

Humanized Cell Line

A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza vi...
Learn More
Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai | P180301US03

Technology

Novel Adjuvant For Animal And Human Vaccines

Quil-A chitosan spherical nanostructure complexes as well as methods of making and using such complexes are disclosed herein. Also provided are Quil-A chitosan spherical nanostrucutres loaded with one...
Learn More
Adel Talaat, Shaswath Chandrasekar | P190189US02

WARF